{"id":7839,"date":"2026-04-19T21:12:12","date_gmt":"2026-04-19T21:12:12","guid":{"rendered":"https:\/\/www.europesays.com\/ai\/7839\/"},"modified":"2026-04-19T21:12:12","modified_gmt":"2026-04-19T21:12:12","slug":"heres-what-td-cowen-thinks-about-tempus-ai-inc-tem-stock","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ai\/7839\/","title":{"rendered":"Here\u2019s What TD Cowen Thinks About Tempus AI Inc (TEM) Stock"},"content":{"rendered":"\n

Tempus AI Inc (NASDAQ:TEM<\/a>) is among the best medical AI stocks to buy now<\/a>. Tempus has partnered with SoftBank, Gilead, and Merck on AI-driven drug development programs. Analysts are growing more confident in Tempus amid its expanding partnerships. On April 13, TD Cowen upgraded Tempus AI Inc (NASDAQ:TEM) to a Buy rating from Hold, though it lowered the price target to $65 from $70. TD Cowen analyst Dan Brennan pointed to the company\u2019s strong fundamentals for the upgrade, though Brennan noted the stock has eased around 50% over the past six months.<\/p>\n

\"Here\u2019s Here\u2019s What TD Cowen Thinks About Tempus AI Inc (TEM) Stock <\/p>\n

According to TD Cowen, Tempus\u2019 Insights business is well-positioned for accelerated growth and forecast beat in 2026. The firm also expects continued growth in Tempus\u2019 Genomics business. Tempus\u2019 revenue increased 83.4% to $1.3 billion in 2025. The company is anticipating 2026 revenue to be $1.59 billion, implying a growth of 25%.<\/p>\n

The Tempus-SoftBank pact, unveiled in June 2024, is structured as a joint venture and involves Tempus bringing its AI-driven treatment and clinical trial recommendations to the Japanese market.<\/p>\n

Japan\u2019s AI in healthcare market size is forecast to reach $2.29 billion by 2034 from $545.3 million in 2025, according to IMARC Group estimates. Factors like the increasing need for personalized medication, growing interest in remote patient monitoring, and the growing need to accurately forecast patient results are driving the market growth.<\/p>\n

Tempus AI Inc (NASDAQ:TEM), based in Chicago, Illinois, offers precision medicine services. It makes use of data and artificial intelligence for this work. Although the company is primarily focused on cancer treatment, it\u2019s expanding into areas like cardiology and infectious diseases. Tempus AI was founded in 2015 by billionaire Eric Lefkofsky.<\/p>\n

While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0best short-term AI stock<\/a>.<\/p>\n

READ NEXT: David Abrams\u2019 Hedge Fund Is Betting On These 8 Stocks<\/a> and 10 Best Energy Storage Stocks to Buy According to Hedge Funds<\/a>.<\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Tempus AI Inc (NASDAQ:TEM) is among the best medical AI stocks to buy now. Tempus has partnered with…\n","protected":false},"author":2,"featured_media":7840,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[24,1147,25,6871,6872,6873,3467],"class_list":{"0":"post-7839","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ai","8":"tag-ai","9":"tag-ai-stock","10":"tag-artificial-intelligence","11":"tag-dan-brennan","12":"tag-td-cowen","13":"tag-tempus","14":"tag-tempus-ai-inc"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/7839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=7839"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/7839\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/7840"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=7839"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=7839"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=7839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}